Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 24 , ISSUE 1 ( January, 2020 ) > List of Articles


Successfully Treated Hepatitis B Positive Refractory Myasthenic Crisis with Rituximab

R Kumar Singh, Deepika Joshi, Shivani Rath

Keywords : Myasthenia gravis, Myasthenic crises, Rituximab

Citation Information : Singh RK, Joshi D, Rath S. Successfully Treated Hepatitis B Positive Refractory Myasthenic Crisis with Rituximab. Indian J Crit Care Med 2020; 24 (1):71-72.

DOI: 10.5005/jp-journals-10071-23320

License: CC BY-NC 4.0

Published Online: 01-01-2020

Copyright Statement:  Copyright © 2020; The Author(s).


Myasthenia gravis (MG) is an autoimmune disorder of neuromuscular transmission, which presents with fluctuating and variable weakness in ocular, bulbar, limb, and respiratory muscles resulting from an antibody-mediated, T-cell-dependent immunologic attack on the postsynaptic membrane of the neuromuscular junction. Although treatment of MG and myasthenic crisis is based on few specific principles, it is highly individualized. We report a successfully treated case of refractory myasthenic crisis who was on a ventilator for 7 months (210 days), perhaps the longest from India, and required multiple cycles of plasma exchange, intravenous immunoglobulin infusion, and one cycle of rituximab. It exemplifies the role of highly individualized therapy and interdisciplinary cooperation in management of refractory myasthenic crisis.

PDF Share
  1. Jaretzki III A, Barohn RB, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis: recommendations for clinical research standards: task force of the medical scientific advisory board of the myasthenia gravis foundation of America. Neurology 2000;55(1):16–23. DOI: 10.1212/WNL.55.1.16.
  2. Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology 2016;87(4):419–425. DOI: 10.1212/WNL.0000000000002790.
  3. Panda S, Goyal V, Behari M, Singh S, Srivastava T. Myasthenic crisis: a retrospective study. Neurol India 2004;52(4): 453–456.
  4. Sharma S, Lal V, Prabhakar S, Agarwal R. Clinical profile and outcome of myasthenic crisis in a tertiary care hospital: a prospective study. Ann Indian Acad Neurol 2013;16(2):203–207. DOI: 10.4103/0972-2327.112466.
  5. Rahul LY, Dakua T, Mukherjee A. Refractory myasthenia gravis treated successfully with rituximab: a case report. Ann Indian Acad Neurol 2017;20(4):436–437. DOI: 10.4103/aian.AIAN_233_17.
  6. Selecky PA, Ziment I. Prolonged respiratory support for the treatment of intractable myasthenia gravis. Chest 1974;65(2):207–209. DOI: 10.1378/chest.65.2.207.
  7. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000;6(4):443–446. DOI: 10.1038/74704.
  8. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83(2):435–445. DOI: 10.1182/blood.V83.2.435.435.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.